Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-06-30

Study Completion Date

2008-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effect of up to 200 mg of PF-00446687 on acute sexual arousal and sexual interest in post menopausal females, as well as examining the safety and toleration of the drug.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.

NCT00482664

Sexual Dysfunction, Physiological

COMPLETED PHASE2

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

NCT01057901

Sexual Dysfunctions, Psychological

TERMINATED PHASE3

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

NCT00996372

Sexual Dysfunctions, Psychological

COMPLETED PHASE3

Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity

NCT00729469

Atrophy Vaginal Diseases

COMPLETED PHASE3

Flibanserin Versus Placebo in Premenopausal Women With HSDD

NCT00491829

Sexual Dysfunctions, Psychological

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Female Sexual Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study period 1, 2 or 3

Group Type EXPERIMENTAL

PF-00446687

Intervention Type DRUG

Single 200mg dose

Placebo Study period 1, 2 or 3

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-00446687

Single 200mg dose

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women who have evidence of Female Sexual Arousal Disorder.
* Women who experience personal distress due to Female Sexual Dysfunction.
* Post menopausal women aged between 45 and 65 years.

Exclusion Criteria

* Women whose sexual dysfunction is limited to certain types of stimulation, situation or specific partners.
* Women who experience pain with sexual intercourse or who have a sexual aversion disorder.
* Women suffering from female sexual dysfunction where the cause is treatable, for example inadequately controlled diabetes or thyroid dysfunction.

Minimum Eligible Age

45 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No